| Regulatory framework for advanced therapy medicinal products in Europe and United States C Iglesias-López, A Agustí, M Obach, A Vallano Frontiers in pharmacology 10, 471441, 2019 | 157 | 2019 |
| Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States C Iglesias-Lopez, M Obach, A Vallano, A Agustí Cytotherapy 23 (3), 261-274, 2021 | 41 | 2021 |
| Current landscape of clinical development and approval of advanced therapies C Iglesias-Lopez, A Agustí, A Vallano, M Obach Molecular Therapy-Methods & Clinical Development 23, 606-618, 2021 | 37 | 2021 |
| Methodological characteristics of clinical trials supporting the marketing authorisation of advanced therapies in the European Union C Iglesias-Lopez, A Agustí, A Vallano, M Obach Frontiers in Pharmacology 12, 773712, 2021 | 13 | 2021 |
| Financing and reimbursement of approved advanced therapies in several European countries C Iglesias-López, A Agustí, A Vallano, M Obach Value in Health 26 (6), 841-853, 2023 | 8 | 2023 |
| Hurdles of environmental risk assessment procedures for advanced therapy medicinal products: comparison between the European Union and the United States C Iglesias-Lopez, M Obach, A Vallano, A Agustí, J Montané Critical Reviews in Toxicology 49 (7), 580-596, 2019 | 8 | 2019 |
| Regulatory framework for advanced therapy medicinal products in Europe and United States. Front Pharmacol 10: 921 C Iglesias-López, A Agustí, M Obach, A Vallano | 7 | 2019 |
| Temporary derogation from European environmental legislation for clinical trials of genetically modified organisms for coronavirus disease 2019 C Iglesias-Lopez Cytotherapy 23 (1), 10-11, 2021 | 2 | 2021 |
| Corrigendum: regulatory framework for advanced therapy medicinal products in Europe and United States C Iglesias-Lopez, A Agustí, M Obach, A Vallano Frontiers in Pharmacology 11, 766, 2020 | 1 | 2020 |
| Methodological Characteristics of Clinical Trials Supporting the Marketing Authorisation of Advanced Therapies in the European Union MA Agustí Escasany, M Obach, A Vallano, C Iglesias-Lopez Frontiers Media, 2021 | | 2021 |
| Clinical and regulatory strategies to support the marketing authorisation of regenerative medicine products in Japan C Iglesias-Lopez HUMAN GENE THERAPY 32 (19-20), A132-A133, 2021 | | 2021 |
| Methodological features of pivotal clinical trials for the current authorised advanced therapies medicinal products in the european union C Iglesias-Lopez, A Agusti, A Vallano, M Obach Cytotherapy 23 (5), S200-S200, 2021 | | 2021 |
| Current landscape of clinical development and approval of advanced therapies MA Agustí Escasany, A Vallano, M Obach, C Iglesias-Lopez Cell Press, 2021 | | 2021 |
| Hurdles of environmental risk assessment procedures for advanced therapies medicinal products C Iglesias-Lopez, A Agusti, M Obach, A Vallano, J Montane Human Gene Therapy 30 (11), A208-A209, 2019 | | 2019 |
| Regulatory framework for advanced therapy medicinal products in Europe and United States MA Agustí Escasany, M Obach, A Vallano, C Iglesias-Lopez Frontiers Media, 2019 | | 2019 |
